---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-234814"
form_type: "8-K"
ticker: "IKT"
cik: "0001750149"
company_name: "Inhibikase Therapeutics, Inc."
filed_at: "2024-10-09T23:59:59+00:00"
generated_at: "2026-05-30T17:25:51.131622+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "low"
source: SEC EDGAR
---

# Inhibikase posts new corporate presentation highlighting PAH clinical program

## Summary
- New company presentation made available on investor relations website October 9, 2024.
- Presentation focuses on clinical development of disease-modifying therapeutics for pulmonary arterial hypertension (PAH).
- No specific financial results, trial data, or guidance disclosed in the filing.

## SEC filing metadata
- accession: 0001193125-24-234814
- form_type: 8-K
- ticker: IKT
- cik: 0001750149
- company_name: Inhibikase Therapeutics, Inc.
- filed_at: 2024-10-09T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750149/000119312524234814/0001193125-24-234814-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750149/000119312524234814/d882180d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-234814
- JSON: https://secwatch.observer/filing/0001193125-24-234814.json
- Plain text: https://secwatch.observer/filing/0001193125-24-234814.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.